EPS beat, 3–6% core growth outlook, bioprocess strength, Masimo synergies, China/respiratory headwinds—read now.
Q1 2026 Earnings Call April 21, 2026 8:00 AM EDTCompany ParticipantsRachel VatnsdalRainer Blair - President, CEO ...
Discover some of the new atopic dermatitis treatments in clinical development that could overcome existing challenges in the ...
The Phase 2 study (NCT06954467) aiming to evaluate the safety and efficacy of JS207 in combination with JS007 included a safety run-in period and a randomized expansion phase, which enrolled patients ...
We have become a design-and-discovery superpower with a hollowed-out production base. President Trump intends to change that.
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...
HIV-1 envelope glycoprotein (Env), a gp120–gp41 trimer, undergoes coordinated conformational changes that drive membrane fusion and allow immune evasion by transiently concealing ...
Eli Lilly, the maker of the popular GLP-1 injectable Mounjaro, has invested heavily in Houston as a biotechnology hub.
Researchers used CRISPR to edit hematopoietic stem cells, creating B cells that produce neutralizing antibodies against HIV, ...
Oxford, UK – 16th April 2026 - Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms ...
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, ...
Astellas manufacturing chief views reliable supply, bridging research as his production 'north star'
For Astellas’ chief manufacturing officer Rao Mantri, Ph.D.—who entered the position a little over a year ago—production is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results